Status:
COMPLETED
Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma
Lead Sponsor:
IRCCS San Raffaele
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Positron Emission Tomography - Computed Tomography (PET-CT) using fluorine-18 fluorodeoxyglucose is a functional imaging diagnostic tool which is widely used In several neoplastic conditions, at initi...
Eligibility Criteria
Inclusion
- patients with refractory multiple myeloma who relapsed after therapy with daratumumab in combination with dexamethasone + bortezomib or dexamethasone + lenalidomide;
- patients capable of expressing informed consent.
Exclusion
- patients with clinical contraindications to the administration of daratumumab;
- patients with coexisting non-hematological neoplastic condition;
- patients\< 18 years;
- patients uncapable of expressing informed consent.
Key Trial Info
Start Date :
May 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06170151
Start Date
May 24 2021
End Date
December 1 2022
Last Update
December 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Irccs San Raffaele
Milan, Italia, Italy